Receptor, Fibroblast Growth Factor, Type 2
"Receptor, Fibroblast Growth Factor, Type 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fibroblast growth factor receptor that is found in two isoforms. One receptor isoform is found in the MESENCHYME and is activated by FIBROBLAST GROWTH FACTOR 2. A second isoform of fibroblast growth factor receptor 2 is found mainly in EPITHELIAL CELLS and is activated by FIBROBLAST GROWTH FACTOR 7 and FIBROBLAST GROWTH FACTOR 10. Mutation of the gene for fibroblast growth factor receptor 2 can result in craniosynostotic syndromes (e.g., APERT SYNDROME; and CROUZON SYNDROME).
MeSH Number(s)
D08.811.913.696.620.682.725.400.178
D12.776.543.750.060.441
D12.776.543.750.750.400.370.750
Concept/Terms
Receptor, Fibroblast Growth Factor, Type 2- Receptor, Fibroblast Growth Factor, Type 2
- BEK Fibroblast Growth Factor Receptor
- BEK Fibroblast Growth Factor Receptor Kinase
- BEK Protein Tyrosine Kinase
- FGFR2 Protein
- Fibroblast Growth Factor Receptor 2
- Fibroblast Growth Factor Receptors 2
- Bek Fgf Receptor Kinase
- Bek-Related Fibroblast Growth Factor-Receptor-1
- Bek Related Fibroblast Growth Factor Receptor 1
Below are MeSH descriptors whose meaning is more general than "Receptor, Fibroblast Growth Factor, Type 2".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptor, Fibroblast Growth Factor, Type 2 [D08.811.913.696.620.682.725.400.178]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.060]
- Receptor, Fibroblast Growth Factor, Type 2 [D12.776.543.750.060.441]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Fibroblast Growth Factor [D12.776.543.750.750.400.370]
- Receptor, Fibroblast Growth Factor, Type 2 [D12.776.543.750.750.400.370.750]
Below are MeSH descriptors whose meaning is more specific than "Receptor, Fibroblast Growth Factor, Type 2".
This graph shows the total number of publications written about "Receptor, Fibroblast Growth Factor, Type 2" by people in Harvard Catalyst Profiles by year, and whether "Receptor, Fibroblast Growth Factor, Type 2" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 3 | 4 |
| 2008 | 4 | 1 | 5 |
| 2009 | 2 | 3 | 5 |
| 2010 | 1 | 4 | 5 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 4 | 6 |
| 2013 | 3 | 1 | 4 |
| 2014 | 5 | 2 | 7 |
| 2015 | 3 | 2 | 5 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 3 | 4 |
| 2018 | 3 | 0 | 3 |
| 2019 | 5 | 4 | 9 |
| 2020 | 4 | 5 | 9 |
| 2021 | 3 | 1 | 4 |
| 2022 | 0 | 4 | 4 |
| 2023 | 1 | 0 | 1 |
Below are the most recent publications written about "Receptor, Fibroblast Growth Factor, Type 2" by people in Profiles.
-
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med. 2023 Jan 19; 388(3):228-239.
-
FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures. Clin Cancer Res. 2022 12 15; 28(24):5431-5439.
-
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022 Nov; 23(11):1430-1440.
-
EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2022 05 02; 12(5):1378-1395.
-
Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. Future Oncol. 2022 Apr; 18(11):1391-1402.
-
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology. 2021 09; 74(3):1429-1444.
-
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 10; 6(10):803-815.
-
Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2. Angew Chem Int Ed Engl. 2021 07 12; 60(29):15905-15911.
-
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 10; 11(10):2488-2505.
-
Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors. Eur J Med Chem. 2021 Aug 05; 220:113499.